에 대한 최신 뉴스 Bruker (NASDAQ:BRKR) 주식

BRUKER CORP

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Red,Stock,Market,Price,Showing,Trader,Phobia,Of,Crisis,War

News

Movers

ANET

ASML

BRKR

COIN

JBHT

MSTR

TSLA

지난주 이들 11개 대형주는 최하의 성과를 보여주었다. 여러분이 보유한 포트폴리오에도 이들이 있나요? Arm 홀딩스(NASDAQ:ARM)는 지난주 가장 성과가 나쁜 대형주 기업으로 31.08% 폭락했다. 이 회사의 주가는 ASML 홀딩 N.V. (NASDAQ:ASML)이 예상보다 저조한 1분기 연간 실적 발표에 영향을 받았다.

지난주 최하 성과 주식: 이 11개의 대형주가 포트폴리오에 있나요?

Bruker Corp

Health Care

General

Bruker Acquires Biocrates Life Sciences Ag, Located In Innsbruck, Austria. Financial Terms Were Not Disclosed

A. New proteoElute nanoflow nLC system features ceramic valves, proteoTrap trapping columns, and TwinScape-enabled predictive maintenance technology
B. Introducing new generation of PepSep Advanced nLC columns to further improve chromatographic resolution, sensitivity and proteomics identifications
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263257&amp;newsitemid=20250602715993&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=17d2f94ec69b3f1e87b36b18a38df92a">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows.

Bruker Launches proteoElute nanoLC System, Advancing Ultra-Sensitive Proteomics

Breakthrough Athena Ion Processor (AIP) delivers up to 35% more peptide and 20% more protein identifications for highest sensitivity proteomics
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263258&amp;newsitemid=20250602810313&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=7ec8a18c42acb3ef4e62e11c4e05f4ab">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced significant further advances in ultra-high sensitivity 4D-Proteomics&#x2122; with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF&#xAE; methods for key biological and clinical research problems with very low sample amounts.

Bruker Unveils New timsUltra AIP System With Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics And Metaproteomics

Bruker Unveils timsMetabo Mass Spectrometer With Advanced TIMS 'MoRE' Scan-Mode

Analysts' ratings for Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bruker, revealing an average target of $48.0, a high estimate of $60.00, and a low estimate of $40.00. This current average has decreased by 18.99% from the previous average price target of $59.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1747918856_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$48.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Bruker's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bruker's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bruker analyst ratings.</a>
<h2>Delving into Bruker's Background</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
<h3>Bruker: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Bruker's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 11.04%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Bruker's net margin is impressive, surpassing industry averages. With a net margin of 2.17%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.3%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Bruker's debt-to-equity ratio surpasses industry norms, standing at 1.16. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Bruker Through The Eyes Of 8 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgraded the rating for UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) from Buy to Neutral. UroGen Pharma shares closed at $4.17 on Wednesday. <a href="https://www.benzinga.com/quote/URGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Heckmann downgraded Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) from Buy to Neutral and announced a $226 price target. Guidewire Software shares closed at $210.84 on Wednesday. <a href="https://www.benzinga.com/quote/GWRE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Lydia Rainforth downgraded the rating for Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Overweight to Equal-Weight. Equinor shares closed at $23.62 on Wednesday. <a href="https://www.benzinga.com/quote/EQNR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Laura Chico downgraded Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) from Outperform to Neutral and lowered the price target from $13 to $8. Vigil Neuroscience shares closed at $2.31 on Wednesday. <a href="https://www.benzinga.com/quote/VIGL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Patrick Donnelly downgraded Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Neutral and cut the price target from $50 to $40. Bruker shares closed at $36.45 on Wednesday. <a href="https://www.benzinga.com/quote/brkr/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GWRE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="607" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-1024x607.png" alt="" class="wp-image-924250" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-1024x607.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-768x455.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

EQNR

GWRE

URGN

VIGL

This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Citigroup analyst Patrick Donnelly downgrades Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Neutral and lowers the price target from $50 to $40.

Price Target

Citigroup Downgrades Bruker to Neutral, Lowers Price Target to $40

Legal

10x Genomics Reaches Patent Litigation Settlement With Bruker; Bruker To Pay $68M In Equal Quarterly Installments Between Q3 2025 And Q2 2026 As Well As Ongoing Royalties On Sales Of Spatial Biology Products Through Life Of Licensed Patents

Bruker And 10x Genomics Settle Patent Disputes And Enter Global Cross-License Agreement, Dismissing All Ongoing Litigations

The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells
AbCellera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ("the ‘408 Patent"). AbCellera's ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells.
Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the ‘408 Patent alleging invalidity based on anticipation and obviousness over the prior art. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker's arguments and now the CAFC has confirmed that all claims of AbCellera's ‘408 Patent are valid. AbCellera's ‘408 Patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the U.S. District Court for the Northern District of California.

ABCL

AbCellera Announces The Federal Circuit Upholds Validity Of Its '408 Patent On Microfluidic Cell-Culturing Devices, Rejecting Bruker Cellular's Invalidity Challenge And Strengthening AbCellera's Position In Ongoing Patent Litigation.

UBS analyst Dan Leonard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Neutral and lowers the price target from $57 to $45.

UBS Maintains Neutral on Bruker, Lowers Price Target to $45

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $50 to $46.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $46

Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Neutral and lowers the price target from $50 to $45.

Goldman Sachs Maintains Neutral on Bruker, Lowers Price Target to $45

Stifel analyst Daniel Arias maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $57 to $48.

Stifel Maintains Hold on Bruker, Lowers Price Target to $48

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) lowers FY2025 Adj EPS guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 analyst estimate. Raises FY2025 sales outlook from $3.47 billion-$3.54 billion to $3.48 billion-$3.55 billion vs $3.48 billion estimate.

Guidance

Bruker Lowers FY2025 Adj EPS Guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 Est; Raises FY2025 Sales Guidance from $3.47B-$3.54B to $3.48B-$3.55B vs $3.48B Est

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.43 by 9.3 percent. This is a 11.32 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $801.40 million which beat the analyst consensus estimate of $764.56 million by 4.82 percent. This is a 11.04 percent increase over sales of $721.70 million the same period last year.

Earnings

Earnings Beats

Bruker Q1 Adj. EPS $0.47 Beats $0.43 Estimate, Sales $801.40M Beat $764.56M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Bruker Says It Will Showcase Major Spatial Biology And Multiomics Innovations At AACR 2025, Highlighting CosMx WTX And 1,200-Plex Protein Panel

Across the recent three months, 6 analysts have shared their insights on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.0, with a high estimate of $65.00 and a low estimate of $50.00. Observing a downward trend, the current average is 17.39% lower than the prior average price target of $69.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744923614_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$75.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $50.00&#x7C;$60.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $50.00&#x7C;$75.00 &#x7C; 
&#x7C;Daniel Arias &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $57.00&#x7C;$70.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $65.00&#x7C;$69.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Bruker's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Bruker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bruker analyst ratings.</a>
<h2>Delving into Bruker's Background</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
<h3>Key Indicators: Bruker's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Bruker showcased positive performance, achieving a revenue growth rate of 14.64% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 1.4%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.76%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bruker's ROA excels beyond industry benchmarks, reaching 0.23%. This signifies efficient management of assets and strong financial health.
Debt Management: Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.26, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Bruker Through 6 Analysts

Wells Fargo analyst Brandon Couillard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $75 to $60.

Wells Fargo Maintains Overweight on Bruker, Lowers Price Target to $60

Press Releases

Bruker and 10x Genomics Reach Global Settlement of Patent Litigation

Bruker Announces Quarterly Dividend

Bruker Introduces Novel MOVE-T System for Transferable, Robust Milk and Liquid Dairy Analysis with FT-NIR Technology

Bruker Launches Novel timsMetabo™ Mass Spectrometer for Breakthrough 4D-Metabolomics and 4D-Lipidomics Sensitivity, Specificity and Annotation Confidence - at Speed, Depth, and Scale

Bruker Launches Revolutionary timsOmniTM Mass Spectrometer

Bruker Corporation to Present at the Jefferies Global Healthcare Conference

Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity

Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics

Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Niagen Bioscience

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Citigroup

Barclays

Goldman Sachs

Stifel

지난주 이들 11개 대형주는 최하의 성과를 보여주었다. 여러분이 보유한 포트폴리오에도 이들이 있나요?
<ol>
<li>Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)는 지난주 가장 성과가 나쁜 대형주 기업으로 31.08% 폭락했다. 이 회사의 주가는 ASML 홀딩 N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)이 예상보다 저조한 <a href="https://www.benzinga.com/news/24/04/38299189/whats-going-on-with-arm-holdings-stock" target="_blank" rel="noreferrer noopener">1분기 연간 실적 발표</a>에 영향을 받았다. 엑산 BNP 파리바(Exane BNP Paribas)의 데이비드 오코너(David O&#8217;Connor) 분석가는 ARM의 목표 가격을 100달러로 유지하며 등급을 <a href="https://www.benzinga.com/quote/ARM/analyst-ratings" target="_blank" rel="noreferrer noopener">&#8220;시장 수익률 상회(Outperform)&#8221;에서 &#8220;중립(Neutral)&#8221;으로 </a>하향 조정했다.</li>
<li>마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)의 주가는 지난주 20.07% 하락했다. 반감기를 앞둔 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) 가격의 변동성때문에 지난주 대부분의 암호화폐 주식이 하락했다.</li>
<li>코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)의 주식은 비트코인(CRYPTO:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/btc-usd" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for BTC/USD">BTC</a>) 가격의 약세로 인해 지난주 15%의 빠졌다. 경제학자인 피터 쉬프(Peter Schiff)는 일부 강세 예측에 맞춰 이 암호화폐가 상승할 것에 대해 회의적인 입장을 <a href="https://www.benzinga.com//node/38265256" target="_blank" rel="noreferrer noopener">표명했</a>다.</li>
<li>프롤로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>)의 주식은 13.73% 하락했다. 이 회사의 2024년 1분기 임대 수익은 18억 3천만 달러로 컨센서스를 하회했으며 예상되는 <a href="https://www.benzinga.com/news/earnings/24/04/38292399/why-prologis-shares-are-trading-lower-today" target="_blank" rel="noreferrer noopener">평균 점유율 감소와 경쟁적 임대</a>로 인해 EPS 및 핵심 FFO/주식에 대한 FY24 전망을 낮췄다.</li>
<li>테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 주식은 지난주 13.6% 하락했다. 일론 머스크가 이끄는 이 회사는 <a href="https://www.benzinga.com//node/38346490" target="_blank" rel="noreferrer noopener">여러 이유로</a> 힘든 1주일을 보냈다. 현재 하락하는 전기차 수요, 사이버트럭 리콜, 직원 감축 및 가격 인하에 직면하고 있다.</li>
<li>에퀴팩스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/efx" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for EFX">EFX</a>)의 주식은 13.54% 빠졌다. 이 회사는 예상보다 나쁜 1분기 판매 실적을 보고했으며 수요일에 <a href="https://www.benzinga.com/news/earnings/24/04/38333254/equifax-analysts-cut-their-forecasts-after-q1-results" target="_blank" rel="noreferrer noopener">추정치보다 낮게 조정된 지침</a>을 발표했다.</li>
<li>브루커 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>)의 주식은 현금 3억 9,260만 달러 나노스트링 테크놀로지스(NanoString Technologies)의 인수를 발표한 후 주가가 11.90% 하락하는 등 힘든 한 주를 보냈다.</li>
<li>라이브 네이션 엔터테인먼트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>)는 11.76% 하락했다. 이 회사의 주식은 법무부가 해당 회사를 상대로 독점 금지 <a href="https://www.benzinga.com/news/24/04/38265894/live-nation-entertainment-groupon-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session" target="_blank" rel="noreferrer noopener">소송을</a> 제기할 것이라는 보도가 나오면서 주가는 하락세를 보였다.</li>
<li>아리스타 네트웍스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>)의 주가는 지난주 10.69% 하락했다. 최근 로젠블라트(Rosenblatt)의 분석가는 목표 가격 210달러로 주식을 &#8220;매도&#8221;로 <a href="https://www.benzinga.com//node/38220808" target="_blank" rel="noreferrer noopener">두 단계</a>  하향 조정했다.</li>
<li>J.B. 헌트 트랜스포트 서비스(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/jbht" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for JBHT">JBHT</a>)의 주가는 지난주 10.47% 하락했다. 1분기 수익은 하위 부문 <a href="https://www.benzinga.com/news/earnings/24/04/38287679/why-j-b-hunt-transport-shares-are-diving-today" target="_blank" rel="noreferrer noopener">총 매출 감소와 선적 감소</a>로 인해 컨센서스 예상치를 밑돌았다. 몇몇 분석가들은 실적 부진 이후 <a href="https://www.benzinga.com/quote/JBHT/analyst-ratings" target="_blank" rel="noreferrer noopener">주식 목표 가격</a>을 낮췄다.</li>
<li>앨버말(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)의 주식은 지난주 리튬 가격의 변동성으로 인해 9%의 가치를 잃었다.</li>
</ol>
참고 자료: <a href="https://www.benzinga.com/news/earnings/24/04/38349264/tracking-last-weeks-top-performers-are-these-7-large-cap-stocks-in-your-portfolio" target="_blank" rel="noopener">지난주 최고 성과 추적: 이 7개의 대형주가 포트폴리오에 포함되어 있나요?</a>
사진: 셔터스톡

Comments

Bruker

뉴스

에 대한 최신 뉴스 Bruker (NASDAQ:BRKR) 주식

월요일, 4월 22, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌